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Abstract.  Lysophosphatidic acid is a product of acti- 
vated platelets and has diverse actions on cells. We 
have characterized the effect of lysophosphatidic acid 
on cell-mediated binding and assembly of fibronectin, 
an extracellular matrix protein.  Serum made from 
whole blood, but neither platelet-poor plasma nor se- 
rum made from platelet-poor plasma,  caused enhanced 
binding of fibronectin to cultured fibroblastic cells. 
The ability of whole blood serum to enhance binding 
of fibronectin was abolished by phospholipase B. 
These results indicate that lysophosphatidic acid de- 
rived from platelets is the principal component in 
whole blood serum that is active in the fibronectin 
binding assay.  1-oleoyl  lysophosphatidic acid, 20-200 
nM,  was as active as 0.1-0.2%  whole blood serum. 
The stimulatory effect of lysophosphatidic acid on the 
binding of fibronectin or the amino-terminal  70-kD 
fragment of fibronectin was rapid,  sustained,  and lost 
upon removal of lysophosphatidic acid.  The stimula- 
tory effect on binding could not be duplicated by 
bradykinin,  platelet-activating factor, bombesin, or a 
peptide agonist of the thrombin receptor.  Enhanced 
binding of the 70-kD fragment was due to increases in 
both the number and affinity of binding sites. En- 
hanced binding and assembly of fibronectin correlated 
with changes in cell shape and actin-containing 
cytoskeleton. The binding sites for fibronectin on 
lysophosphatidic acid-stimulated cells, as assessed by 
fluorescence, video, and scanning electron microscopy, 
were on areas of cell membrane containing numerous 
filopodia that extended between cells or between cells 
and substratum.  These observations suggest that 
lysophosphatidic acid functions as a powerful and 
specific modulator of cell shape and early matrix as- 
sembly during  wound healing. 
YSOPnOSPHArIOIC acid (LPA)  ~ is an  intermediate  for 
de novo lipid biosynthesis (Bishop  and Bell,  1988) 
and is generated rapidly upon cell activation  (Billah 
et al., 1981; Lapetina et al., 1981; Watson et al., 1985; Ger- 
rard and Robinson,  1989; Exton, 1990). As a result of plate- 
let activation during coagulation of whole blood, the concen- 
tration of LPA in serum is 1-5/~M (Eichholtz  et al., 1993). 
Extracellular  LPA has may biological effects. These include 
mobilization  of intraceUular  Ca  2÷ (Moolenaar et al.,  1986; 
Jalink et al., 1990); inhibition of adenylate cyclase, stimula- 
tion of phospholipase C, and activation of protein kinase C 
(van Corven et al., 1989); regulation of p21ras (van Corven 
et al., 1993); stimulation of mitogen-activated  protein kinase 
(Howe and Marshall,  1993);  stimulation  of tyrosine phos- 
phorylation of phosphatidylinositol  3-kinase, focal adhesion 
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kinase and paxillin  (Kumagal et al.,  1993; Seufferlein and 
Rozengurt,  1994);  stimulation  of focal adhesion  and actin 
stress fiber formation  (Ridley and Hall, 1992); retraction  of 
neuronal  cells  (Jalink  et al.,  1993);  induction  of smooth 
muscle cell contraction (Tokumura et al.,  1980); activation 
of platelets  (Benton et al.,  1982);  and induction  of mito- 
genesis (van Corven et al., 1989). The effects of LPA on cell 
morphology are striking  and involve the GTP-binding  pro- 
tein p21rho (Ridley and Hall, 1992; Miura et al., 1993; Ku- 
magai et al., 1993; Jalink et al., 1994). A 55-kD LPA-bind- 
ing  protein has been identified  on the surface of cells by 
covalent crosslinking and conjectured to be a G-protein cou- 
pled receptor for LPA (van der Bend et al., 1992). Thus, LPA 
may stimulate cells by pathways similar to platelet-activating 
factor (1-O-alkyl-2-acetyl-sn-glycerol-3-phosphocholine),  a 
bioactive lipid  with a  known  G-protein coupled receptor 
(Prescott et al., 1990; Nakamura et al., 1991). Failure ofin- 
tracellularly  generated  or rnicroinjected  LPA to mimic the 
action of extracellular  LPA (Watson et al.,  1985; Fernhout 
et al., 1992) also implies the existence of a cell surface LPA 
receptor. 
Fibronectin is a dimeric glycoprotein  found at high con- 
centrations  in plasma and other body fluids and in an insolu- 
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(Mosher,  1989; Hynes, 1990).  Fibronectin is necessary for 
normal embryogenesis (George et al.,  1993).  Insoluble tis- 
sue fibronectin has several  likely biological functions, in- 
cluding promotion of cellular migration during embryogene- 
sis and wound healing (Colvin,  1989;  Thiery et al.,  1989; 
Hynes, 1990; Welch et al.,  1990).  Deposition of plasma or 
cell-derived fibronectin into extracellular matrix is initiated 
by the binding of the soluble fibronectin to cell surface sites 
in a  specific and saturable manner (McKeown-Longo and 
Mosher,  1983;  Peters and Mosher,  1987a;  Allio and Mc- 
Keown-Longo, 1988).  Reversibly bound fibronectin then is 
polymerized into  high molecular weight multimers (Mc- 
Keown-Longo and Mosher, 1984; Barry and Mosher, 1988, 
1989). 
Serum influences elaboration of fibronectin matrix by cul- 
tured cells (Mautner and Hynes, 1977; Mosher and Vaheri, 
1978;  Rennard et at.,  1981; Singer,  1982,  1989).  We re- 
cently identified LPA as a  potent enhancer of fibronectin 
binding and assembly by cultured adherent cells (Checovich 
and Mosher, 1993). As discussed by Eichholtz et at. (1993), 
serum LPA has the potential to be an important mediator of 
wound healing. Therefore, we investigated how much of the 
stimulatory activity of serum on fibronectin binding to cells 
can be attributed to LPA. We then explored the mechanism 
by which LPA stimulates binding of fibronectin to cells. We 
focused on the specificity of the response to LPA, whether 
LPA acts upon fibronectin or cells, the time course of re- 
sponse to LPA, alterations in kinetics of binding of the 70- 
kD amino-terminal region that mediates the reversible inter- 
action of fibronectin with cells,  and correlations between 
state of the actin-containing cytoskeleton and binding of 
fibronectin to LPA-stimulated cells. 
Materials and Methods 
Materials 
LPAs with different fatty acids at the 1-position were obtained from Avanti 
Polar Lipids (Birmingham, AL). Bradykinin, bombesin, fatty acid-free bo- 
vine albumin, phospholipase A2 from bee venom, phospholipase B from 
Vibrio species, platelct-activating factor, prostaglandin El, and a thrombin 
receptor peptide agonist (SerPheLcuLeuArgAsnProAsnAspLysTyrGluPro- 
Phe) were purchased from Sigma Chem. Co.  (St.  Louis,  MO).  Human 
thrombin was a gift from Dr. J.  Fanton (New York State Department of 
Health, Albany, NY). Rbodamine-phalloidin and FITC were from Molecu- 
lar Probes (Eugene, OR). 
Human  plasma  fibronectin and  the  70-kD  amino-terminal,  gelatin- 
binding fragment of fibronectin generated by cathepsin D were isolated, io- 
dinated,  and  reisolated as  previously described (McKeown-Longo and 
Mosher,  1983,  1985).  The labeled pro~ins  were stored in  portions at 
-70°C in TBS (Tris hydrochloride, 20 raM, pH 7.4; sodium chloride, 150 
mM) containing 0.1% (wt/vol) fatty acid-free bovine albumin. Purity of la- 
beled proteins was assessed by SDS-PAGE with and without reduction fol- 
lowed by autoradiography. The concentration of 1251-70-kD fragment for 
calculation of specific activity was determined as follows. Dilutions of la- 
beled 70-kD fragment and of known amounts of unlabeled 70-kD fragment, 
all in 0.1% albumin, were bound in a batch mode to gelatin-agarose. After 
the affinity matrix was washed, bound protein was elated with SDS sample 
buffer,  subjected to  SDS-PAGE,  and quantified by densitometry of the 
stained gel. Fibronectin and the 70-kD fragment were also labeled with 
FITC (McKeown-Longo and Mosher, 1983,  1985). 
Preparation of  Plasma and Serum 
Plasma and serum were made on the day of the experiment from a freshly 
drawn blood sample (Eichholtz ct at., 1993). For plasma, six parts of  blood 
were mixed in a polypropylene tube with one part of ACD (0.8% citric acid, 
2.2% trisodium citrate, 2.45% glucose, pH 5) and made 100 nM in prosta- 
glandin El. Red cells were removed by centrifugation for 15 min at 120 g. 
The supernatant was titrated to pH 6.5 with additional ACD, and platelets 
were removed by centrifngation for l0 min at 1200 g. Remaining cell debris 
was removed by two additional centrifugations for 5 rain at 8000 g. For se- 
rum, blood was placed in a glass tube, made 1 U/ml with human t~-throm- 
bin, and set at 37°C for 30 min. The retracted clot was removed by centrifu- 
gation at 3000 g  for 2 min, and serum was further centrifuged twice for 
5 rain at 8000 g. For plasma-serum, platelet-poor plasma made as above 
was incubated with l  U/ml human a-thrombin and 10 mM calcium ion in 
excess of citrate at 37°C for 30 rain. The concentrations of the platelet gran- 
ule protein, thrombospondin, in these samples were measured by ELISA 
(Jaffe et al., 1983) and were 0.7 p.g/ml in plasma and plasma-serum and 8.3 
#g/ml in whole blood serum. The clot was removed by centrifugation at 
3000  g  for 2  min,  and plasma-serum was further centrifuged twice for 
5 min at 8000 g.  Plasma or serum was diluted in four parts of Tyrode's 
buffer 050 mM sodium chloride, 2.5 mM potassium chloride, 12 mM so- 
dium bicarbonate,  1 mg/ml glucose, 2 mM magnesium chloride, pH 7.4) 
and treated for 60 min at 37°C with phospholipase A2 or B, 3 U/ml. Cal- 
cium chloride, 2.5 mM in excess of citrate, was added to the samples con- 
taining  phospholipase A2.  The  plasma  and  serum  samples were  then 
diluted further in Tyrode's buffer containing 0.2 % fatty acid-free bovine al- 
bumin so that the final  concentrations in the binding assays were 2% or 
lower. Controls included plasma or serum incubated without phospholipase 
and phospholipases incubated without plasma or serum. 
Cell Culture 
The MG63 human osteosarcoma cell line was obtained from the American 
Type Culture Collection (Rockville, MD). Human foreskin fibroblasts were 
a  strain derived by Dr.  Lynn Allen-Hoffman (University of Wisconsin- 
Madison). Cells were cultured in DME (GIBCO BRL, Gaithersburg, MD) 
supplemented with 5 % (for MG63 cells) or 10% (for foreskin fibroblasts) 
FBS (Intergen, Purchase, NY). Cells for experiments were seeded at 40,000 
cells/2-cm  2 well (24-well plates; Costar, Cambridge, MA) and were stud- 
ied when newly confluent 2-3 d after seeding. 
Binding Assays 
Cell layers were washed twice with TBS and incubated in Tyrode's buffer 
and 0.2% fatty acid-free bovine albumin for binding assays of <l-h dura- 
tion. DME containing 0.2 % fatty acid-free bovine albumin, 10 mM Hepes, 
pH 7.4,  was used in the longer time course studies. The binding mixtures 
contained radiolabeled fibronectin (usually 1 #g/mi, '~150,000  cpm/well) 
or 70-kD fragment (usually 0.2 #g/mi, ,',,150,000 cpm/well) and various ad- 
ditives in 0.5 mi. After 45 rain (except in the case of time-course experi- 
ments) at 37°C, cell layers were washed and assayed for the amounts of 
total  cell layer-associated radioactivity (Checovich and  Mosher,  1993). 
Nonspecific binding in the presence of 500 #g/mi of unlabeled fibronectin 
or 50 #g/ml of unlabeled 70-kD fragment ("o10-30% of total binding for 
both intact fibronectin and the 70-kD fragment) was subtracted from total 
binding to calculate specific binding. Total cell protein was also determined 
(Lowry ct at., 1951). Comparative assays showed that 1 mg of cell protein 
represented 4.6 and 4.7  x  106 cells for the MG63 cells and foreskin fibro- 
blasts under the experiment conditions, respectively. The amount of fibro- 
nectin or 70-kD fragment bound per mg cell protein varied up to twofold 
from experiment to experiment. Replicate wells within a given experiment, 
however, usually varied <5 %. 
For binding isotherms at equilibrium, confluent cell layers in the absence 
or presence of LPA were incubated at 37°C for 45 min with increasing con- 
centrations of 1251-70-kD fragment without or with an excess of unlabeled 
70-kD fragment. Data were analyzed by Scatchard and Hill plots (Limbird, 
1986).  Association rate constants, kl,  were estimated from amounts of 
12~I-70-kD fragment specifically bound after 2 min of incubation at input 
concentrations of 0.05,  0.1, 0.2, and 0.4 ttghnl. The concentration of po- 
tential  binding sites was assumed to be that determined in the 45-min 
equilibrium-binding studies. Dissociation rate constants, k-i, of bound 70- 
kD fragment were estimated by monitoring ligand appearing in the medium 
after a 45-rain binding assay. Rate constants were calculated as described 
by Limbird (1986).  Plots to estimate kl and k-i  were linear in all cases 
(r  2 >  0.92). 
Microscopy 
Video-enhanced light microscopy was performed as described previously 
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a glass perfusion chamber and viewed over a 40-min period at 25°C with 
a high-magnification, video-enhanced  microscope built on a Nikon Diaphot 
(Garden City, NY). Images were projected to a DAGE-MTI Newvicon cam- 
era (Michigan City, IN) modified for manual control of gain and black level. 
A video-processor and attendant synchronization stripper (Colorado Video 
604 and 302-2, Boulder, CO) allowed nonlinear expansion of contrast and 
brightness. Experiments were recorded with a high-resolution VCR (NV 
9240XD; Panasonic, Secaucus, N J), and selected images were routed to an 
MS-DOS 80386-based computer equipped with video capture and process- 
ing hardware (Imaging Technology, Inc., Woburn, MA). 
For fluorescence microscopy of bound fibronectin or 70-kD fragment in 
cell layers (McKeown-Longo and Mosher, 1983,  1985),  cells cultured on 
glass coverslips were incubated with FITC-labeled fibronectin or 70-kD 
fragment (20 or 4.5 #g/ml, respectively) in the absence or presence of 200 
nM  1-oleoyl LPA for 45 min at 37°C. For actin localization (Ridley and 
Hall,  1992),  cells were fixed in 3%  paraformaldehyde for 20 min, per- 
meabilized with 0.2 % Triton X-100 for 5 min, and incubated with 0.1 #g/nil 
rhodamine-labeled phalloidin for 20 min. Coverslips were mounted with 
glycerol gel (Sigma Chem.  Co.) and cells were viewed on a  Nikon epi- 
fluorescence microscope. Care was taken to photograph a  given fluoro- 
chrome at the same settings for all experimental permutations. 
For immunoelectron microscopic localization of bound fibronectin, cells 
cultured on plastic coverslips (Nunc, Inc., Naperville, IL) were incubated 
with 20 #g/ml FITC-labeled fibronectin in the absence or presence of 200 
nM LPA for I h at 37°C. Cells were washed, prefixed, and labeled with rab- 
bit anti-fluorescein antiserum (1:100 dilution) followed by secondary don- 
key anti-rabbit IgG antibodies conjugated to 18-nm gold beads as described 
(Peters et al., 1990; Dzamba and Peters, 1991). After the immunolabeling, 
cells were washed with TBS, pH 8.2, containing 20 mM sodium azide and 
1% bovine albumin, and post-fixed  with 2.5 % glutaraldehyde and then 0.1% 
osmium tetroxide,  both  in  0.1  M  Hepes,  pH  7.0. Post-fixed cells were 
washed,  dehydrated with  ethanol,  and  critical  point dried  (Peters  and 
Mosher, 1987a). The cells were examined on a Hitachi S-900 high resolu- 
tion, low voltage, scanning electron microscope at the Integrated Micros- 
copy Resource of the University of Wisconsin. 
Results 
Serum is known to enhance binding of fibronectin to cell 
layers, as described in the Introduction. To test whether LPA 
accounts for the enhancing  effect of serum on fibronectin 
binding, whole blood serum and citrated plasma were made 
the day of experimentation from a freshly drawn blood sam- 
ple and treated with phospholipases.  In addition,  plasma- 
serum  was  prepared  from citrated  plasma by addition  of 
thrombin  and  excess  Ca  2÷  after the  removal of platelets, 
white cells, and red cells. Plasma and serum samples were 
diluted in calcium-free Tyrode's buffer containing 0.2 % fatty 
acid-free bovine albumin so that the final concentrations in 
the fibronectin binding assay were 2 % or lower (Fig.  1 A). 
200-fold more plasma or plasma-serum than whole blood se- 
rum was required to cause equivalent enhancement of bind- 
ing of fibronectin to MG63 osteosarcoma cells. Prostaglandin 
E,,  which  was  added  to the blood that was processed to 
plasma in order to minimize platelet activation, was present 
in the assays of plasma or plasma-serum at concentrations 
up to 2  nM.  In control experiments, this concentration of 
prostaglandin  E~  had  no  effect on  binding  of fibronectin 
(data not shown). When whole blood serum was treated with 
phospholipase B, which hydrolyzes acyl bonds at the 1- and 
2-positions of LPA, the enhancement activity for fibronec- 
tin binding was lost (Fig.  1 B).  When whole blood serum 
was treated with phospholipase A2, which hydrolyzes at the 
2-position, activity was not altered.  Phospholipase A2,  in- 
stead, generated activity in plasma (Fig.  1 B), presumably 
due to hydrolysis of phosphatidic acid to form LPA. Taken 
together with the studies of Eichholtz et al.  (1993),  these 
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Figure 1. Effects of plasma and serum on binding of fibronectin to 
MG63 osteosarcoma  cells.  (A) Fresh human plasma (P), whole 
blood serum (S),  or plasma-serum  (PS) was prepared and added 
to MG63 cells at the designated dilution for 45 min with 1 #g/ml 
t25I-fibronectin (FN).  Specific  binding  was  determined  as  de- 
scribed  in the Methods.  (B) Fresh human plasma (P) or whole 
blood serum (S) was prepared and incubated alone, with phospholi- 
pase A2 (+PLA2),  or with phospholipase B (+PLB) as described 
in Methods and tested in a 45-min binding assay as in A. Points rep- 
resent averages of duplicate values that varied <5 %. 
results indicate that the active component in whole blood se- 
rum that enhances fibronectin binding to MG63 cells is a 
product of platelet activation and is LPA. 
Binding of t25I-fibronectin  to human MG63 osteosarcoma 
cell monolayers was enhanced in the presence of increasing 
concentrations of LPA containing four different fatty acids 
(Fig. 2 A).  1-oleoyl LPA was the most potent stimulator fol- 
lowed by the palmitoyl, stearoyl, and myristoyl LPAs. Inas- 
much as binding of soluble fibronectin to substrate-attached 
cells is mediated principally by the 70-kD amino-terminal 
region of fibronectin (McKeown-Longo and Mosher,  1985, 
1989),  we tested the effects of the four different LPAs on 
binding of ~zsI-70-kD fragment to MG63 cells (Fig.  2 B). 
Enhancement of binding of 70-kD fragment was comparable 
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~25I-labeled fibronectin (FN) to MG63 osteosarcoma  cells by in- 
creasing concentrations of 1-oleoyl-LPA. Each data set was calcu- 
lated as the ratio of specific binding measured in the presence and 
absence of LPA (that is, binding in the absence of LPA =  1). Bind- 
ing in the presence of  an additional 1140 nM (500/zg/ml) unlabeled 
fibronectin was considered to be nonspecific and subtracted to cal- 
culate specific binding. Control values in the absence of LPA (input 
fibronectin concentration in nM, specifically bound fibronectin in 
ng/mg) were: 0.6, 8; 0.8, 9; 2.6, 22; 21,  170; and 200,  1140. Each 
point represents the average of duplicate values that varied <5 %. 
Figure 2. Effects of various LPAs on binding of fibronectin or 70- 
kD amino-terminal fragment to MG63 osteosarcoma cells. Increas- 
ing concentrations of 1-oleoyl (ole), 1-myristoyl (myr),  1-palmitoyl 
(pal), or 1-stearoyl (ste) LPA were incubated for 45 rain with (A) 
1 /~g/ml radiolabeled  fibronectin  (FN) or (B)  0.2  #g/ml 70-kD 
amino-terminal fragment of fibronectin (70 kD). Points represent 
specifically bound fibronectin or 70-kD fragment and are averages 
of duplicate values that varied <5 %. 
with that observed with whole fibronectin in terms of both 
dose responses and relative activities of the LPAs. 
LPA at similar doses caused similar enhanced binding over 
a  range of fibronectin concentrations  from 0.6  to 200 nM 
(Fig. 3). These results indicate that LPA acts not by stoichio- 
metric combination with fibronectin but by enhancement of 
the ability of cells to bind fibronectin. 
The  increase of fibronectin binding  to  MG63  cells was 
significant for up to 24 h of exposure of cells to 200 nM LPA 
when  ~25I-fibronectin was present throughout the treatment 
period (Fig. 4 A). The difference between control and LPA- 
treated  cell  layers,  however, diminished  during  this  time 
(Fig.  4  A).  Bound  ~25I-fibronectin in both LPA-treated and 
control cellAayers at times >45 min was partly in the form 
of high molecular weight multimers when analyzed by SDS- 
PAGE without reduction (data not shown). These results in- 
dicate that LPA-enhanced binding of fibronectin to cell layers 
is coupled to deposition of fibronectin in SDS-insoluble ma- 
trix and that the major enhancing effect of LPA occurs in the 
first 4  h  of incubation.  When the 70-kD fragment,  which 
does not form multimers and accumulate in the  cell layer 
(McKeown-Longo and Mosher, 1985), was tested, enhanced 
binding to cell layers treated with 200 nM LPA was maximal 
at 1-2 h and gradually decreased to control values at 8 h (Fig. 
4 A). A series of experiments were performed to understand 
why the LPgs effect is lost over time. To test whether cells 
would become refractory to LPA, cells were incubated with 
LPA, washed, and then given 12SI-labeled fibronectin or 70- 
kD  fragment along with  fresh LPA.  Cells  incubated  with 
LPA at all time points bound more fibronectin or 70-kD frag- 
ment than control cells when incubated with fresh LPA (Fig. 
4 B).  These results suggest that cells remain responsive to 
LPA and that the results shown in Fig. 4 A are due to loss 
of the activity of LPA upon incubation with cell layers. To 
test stability, LPA was incubated with cells for various lengths 
of time, then half of the medium was transferred to a  new 
well containing cells that had not been pretreated with LPA 
and the other half was left with the original cells (Fig. 4 C). 
Binding assays with 12~I-70-kD fragment showed that LPA- 
containing medium conditioned by cells lost ability to en- 
hance binding to naive cells in parallel with loss of ability 
to  enhance  binding  to  the  original  ceils.  LPA-containing 
medium incubated at 37°C and not placed over cells, in con- 
trast,  retained the ability to enhance binding  when subse- 
quently added to cells. The activity of 200 nM LPA decayed 
to baseline more rapidly than the activity of 2,000 nM LPA 
(Fig. 4 D). In experiments not shown, LPA was added to con- 
ditioned medium from which the activity of a prior addition 
of LPA had been lost.  The second addition of LPA had the 
expected activity. These results indicate that loss of activity 
is  not  due to  the presence of an inhibitor  in  conditioned 
medium and therefore that an efficient cell-based system ex- 
ists to destroy LPA or to remove LPA from culture medium. 
The enhancement of fibronectin binding to MG63 cells by 
The Journal of Cell Biology, Volume  127, 1994  1450 Figure 4.  Duration of the LPA effect on binding of fibronectin or the 70-kD amino-terminal fragment to MG63 osteosarcoma cells. (A) 
Cells were incubated with 1 /~g/ml radiolabeled fibronectin (FN) or 0.2/~g/ml 70-kD amino-terminal fragment (70 kD) in the presence 
or absence of 200 nM  1-oleoyl LPA, and radioactivity associated specifically with cell layer was measured at the indicated time points. 
When data were replotted as mol 70-kD fragment or 240-kD half fibronectin (monomer) per mg cell protein, molar amounts bound at 
1.75 h were nearly identical. (B) Cells were preincubated with or without 200 nM LPA for the designated lengths of time. The medium 
was removed and replaced with a fresh portion of the same medium containing 125I-labeled  binding ligand. A 45-min binding assay was 
performed. (C) Cells were preincubated in medium with or without 200 nM LPA for the designated lengths of time. Half of the medium 
from each well was transferred to a new well containing cells that had not been treated with LPA. t251-70-kD  fragment in a small volume 
was then added to both the wells containing cells incubated with LPA (and containing the remaining half of the medium) (ORIGINAL 
WELL) and the wells to which the medium was transferred (TRANSFER WELL), and 45-min binding assays were performed. The experi- 
ment was planned so that medium with or without LPA was kept in the 37°C incubator for the full 24 h and added to cells at intervals 
to allow the binding assays to be carried out together. Thus, the decay in LPA activity cannot be attributed to time that the LPA-containing 
medium was in the incubator, because this time was constant. (D) Different concentrations of 1-oleoyl LPA were preincubated with cells. 
After different lengths of time, half of the medium from each well was transferred to a new well containing cells that had not been treated 
with LPA, and binding assays of ~251-70-kD fragment were performed as in C. Data represent averages of duplicate values that varied <5 %. 
LPA was observed within 10 min after the addition of LPA 
and ligand (Fig. 5). Time course of enhanced binding in re- 
sponse to LPA up to 4  h  were the same in the presence or 
absence of 10 #g/ml cycloheximide (data not shown),  sug- 
gesting that no protein synthesis is required for enhancement 
of  binding.  The  sustained  stimulation  of  125I-fibronectin 
binding to MG63 cells by LPA contrasted with the effect of 
bradykinin, thrombin receptor peptide, or platelet-activating 
factor (Fig. 5). These agents, like LPA, elevate cytosolic cal- 
cium level in suspended fibroblasts (Jalink et al.,  1990;  Ye 
et al.,  1991;  Jalink and  Moolenaar,  1992).  Bradykinin or 
thrombin receptor peptide caused only transient and small, 
albeit significant (P <  0.05), enhanced binding of fibronectin 
at 10 to 40 min. Platelet-activating factor did not cause any 
enhancement.  Bombesin closely mimics the effects of LPA 
on cytoskeleton and cell shape (Ridley and Hall,  1992).  In 
separate experiments,  bombesin at  concentrations of 1  to 
100  nM  also caused no enhancement of binding of 70 kD 
(data not shown). 
Three independent analyses of the isotherms of binding of 
~251-70-kD fragment to LPA-treated and control MG63 cells 
after 45  min at 37°C  indicated that LPA causes changes in 
both the number of receptor sites per cell (177,000  +  4,000 
for LPA-treated cells and 96,000  +  6,000 for control cells) 
Zhang et al.  Fibronectin  and Lysophosphatidic  Acid  1451 Figure 5. Time course of binding of fibronectin to MG63 osteosar- 
coma cells in the presence of various agonists. Cells were incubated 
for the indicated time with  1 #g/ml  t25I-fibronectin (FN) and no 
agonist (C), 200 nM 1-oleoyl LPA (LPA), 1 #M bradykinin (BK), 
25  #M  thrombin  receptor-activating peptide  (TRP),  or  1  #M 
platelet-activating  factor (PAF). Each data set was calculated as the 
ratio of specific binding measured in the presence and absence of 
potential agonist (binding in the absence of agonist =  1). Points rep- 
resent the mean ratios  +SD (n  =  3). 
and Kd (3.0  +  0.3  nM  for LPA-treated cells and 9.1  +  0.7 
nM  for  control  cells)  (Fig.  6  A).  Scatchard  plots  were 
monophasic and compatible with  single classes of binding 
sites on both LPA-treated and control cells (Fig. 6  B).  Hill 
plots  revealed  no  evidence  of  cooperative  binding  (not 
shown).  The change in affinity caused by LPA could be at- 
tributed  to  an  increased  rate  of association of  12sI-70-kD 
fragment and a  decreased rate of dissociation of bound ~251- 
70-kD  fragment.  Observed  association  rate  constants  of 
J2~I-70-kD  fragment of LPA-treated and control cells were 
4.8  x  1@ and 3.4  ×  104  M-'  sec  -l, respectively. The dis- 
sociation rate constants  were  independent of whether  t2~I- 
70-kD fragment had been bound to the cells in the presence 
or absence of LPA (Fig. 6 C). The rate constants of dissocia- 
tion were 2.2  x  10  -4 sec  -~ in the presence of LPA and 3.8 
x  10  -4 sec  -~ in the absence of LPA. 
The effects of various sequences of preexposure to 200 nM 
LPA on  LPA-enhanced fibronectin binding to  MG63  cells 
were tested (Fig. 7).  Cells preincubated with LPA, with or 
without an intervening interval, responded to LPA during the 
binding  assay  as  well as  previously untreated  cells.  Cells 
from which LPA had been withdrawn at the beginning of the 
binding assay bound the same low level of fibronectin as con- 
trol cells that had not been exposed to LPA at all. Similar 
results were obtained with binding of the 70-kD  fragment 
(not shown). 
Figure 6.  Kinetics of binding of 1251-70-kD amino-terminal frag- 
ment to MG63 osteosarcoma cells. (A) Increasing amounts of t25I- 
70-kD fragment (70 kD) were incubated in 0.5 ml of modified Ty- 
rode's buffer in the absence or presence of 200 nM  1-oleoyl LPA 
with cell layer for 45 min. To achieve concentrations <0.5 ttg/ml, 
ligand with a specific activity of 700 cpm/ng was added. To achieve 
concentrations >0.5/~g/ml, unlabeled 70-kD fragment was added 
to t251-70-kD fragment to yield mixtures with progressively lower 
specific activity. Specific binding was calculated by subtraction of 
nonspecific binding (in the presence of 50/zg/ml or 710 nM unla- 
beled 70-kD fragment) from total binding and expressed as ng 70- 
kD fragment bound per well. Points represent mean +SD (n =  3). 
Cultures were in 2-cm  2 wells each containing approximately 4.3 
x  1@ cells. Scatchard analyses were performed on these data and 
are shown in B. (C) Cells were incubated with 1/~g/ml 1251-70-kD 
fragment for 45 min in the absence (-/) or presence (+/) of 2'00 
nM  1-oleoyl LPA. After rapid washing, the binding mixture was 
replaced with Tyrode's buffer containing 0.2%  fatty acid-free bo- 
vine albumin with (/+) or without (/-) 200 nM LPA. At the desig- 
nated  time points,  small portions of medium  were  sampled to 
estimate dissociation of specifically bound ligand as described in 
Methods. 
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rites (Jalink et al., 1993) and contraction of smooth muscle 
cells (Tokumura et al., 1980). Therefore, we monitored cells 
by phase microscopy as we added or washed out LPA in all 
binding experiments. Binding results correlated with rapid 
changes  in  cell shape (not  shown).  In order to  document 
these shape changes in the same area of the cell layer, we car- 
ried out additional studies in which  MG63  cells were ob- 
served by video-enhanced light microscopy in a  perfusion 
chamber through which LPA could be added or withdrawn 
(Fig. 8). In the absence of LPA, MG63 cells were plump and 
Figure 7. Effect of incubation order on the enhancement by 1-oleoyl 
LPA of fibronectin  binding to MG63 osteosarcoma cells. Cells were 
incubated twice for 1 h each, with three quick washes with TBS 
(total wash time of 5 min) between each incubation, and then in- 
cubated for 45 min with radiolabeled fibronectin (FN). When pres- 
ent (+), the concentration of LPA during the incubations and/or 
binding assay was 200 nM.  Bars represent mean  +SD (n  =  3). 
Figure 8. Effect of 1-oleoyl LPA on MG63 osteosarcoma cell morphology. Phase-contrast micrographs of adherent MG63 cells maintained 
in modified Tyrode's buffer at 22°C. Cells were exposed to 200 nM LPA and photographed at time zero (A) and after l0 min (B). Medium 
was replaced with the modified Tyrode's buffer alone for 20 min (C), followed by readdition of 200 nM LPA for 4 min (D). Arrows indicate 
the cell comer described in the text. Bar,  10 #m. 
Zhang et al. Fibronectin and Lysophosphatidic Acid  1453 Figure  9.  Scanning electron microscopy of control and LPA-treated MG63 osteosarcoma cells. Cells were incubated for 1 h with FITC- 
fibronectin without (A and C) or with (B and D) 200 nM LPA. FITC-fibronectin was localized with anti-fluorescein antibodies and 18-nm 
colloidal gold beads bound to secondary antibodies as described in Methods. Control cells (A) are plump whereas cells treated with LPA 
(B) are flattened and have numerous filopodial extensions. Examination of cells at higher magnification revealed that most (>90%) gold- 
labeled anti-fluorescein antibodies on both control (C) and treated (D) cells were localized at the edges of cells or where cells overlapped. 
These areas were rich in filopodia on LPA-treated cells. The beads were arranged in linear arrays on the dorsal surface or edges of ceils 
(arrowheads) where filopodial extensions are found or on the filopodia themselves (arrows). Bars: (A) 4.8/~m;  (B) 3.8/~m; (C and D) 
0.48 #m. 
overlapped one another (Fig. 8 A). Cells began to retract as 
early as 2 min after addition of LPA. Within 10 min, spaces 
were present between cells that contained numerous cellular 
protrusions (Fig.  8 B).  The arrow indicates an area where 
this retraction is particularly prominent. As with enhanced 
binding  of fibronectin  shown  in  Fig.  7,  the  morphologic 
change was reversible. Following removal of LPA, cells re- 
laxed and gradually spread into the vacated areas. The cor- 
ner marked by the arrow was restored in less than 20 min 
(Fig.  8  C).  Upon  the  readdition  of LPA,  cells  retracted 
quickly, and within 4 min the marked corner was lost (Fig. 
8D). 
The changes in cell shape caused by LPA were also dra- 
matic when observed by scanning elec~on microscopy (Fig. 
9,  A  and B).  LPA-treated cells were flatter than cells not 
treated with LPA and had numerous filopodia that extended 
off  the cell surface and onto neighboring cells or substratum. 
Changes in actin-containing cytoskeleton induced by LPA 
(Ridley and Hall, 1992) were correlated with enhanced bind- 
ing of fibronectin to MG63 cells and foreskin fibroblasts by 
double  label  fluorescence  microscopy with  FITC-labeled 
fibronectin and rhodamine-phaUoidin (Fig.  10).  After addi- 
tion of 200 nM LPA, MG63 cells had a better developed net- 
work  of  phalloidin-stained  microfilament  bundles  when 
compared to cells not treated with LPA (Fig.  10, B and D). 
A  network of long, parallel microfilament bundles,  which 
was well developed in control foreskin fibroblasts (Fig.  10 
F), exhibited increased densities and apparent diameters of 
bundles after treatment with LPA (Fig.  10 H).  After a 45- 
min  incubation  with  either MG63  cells or foreskin fibro- 
The Journal of Cell Biology, Volume 127,  1994  1454 Figure  10. Effect of 1-oleoyl LPA on actin microfilament bundling and binding of exogenous plasma fibronectin to MG63 osteosarcoma 
cells (A-D) and foreskin fibroblasts (E-H). Cell layers on coverslips were incubated with FITC-labeled fibronectin (.4, C, E, and G) in 
the absence (.4, B, E, and F) or presence (C, D, G, and H) of 200 nM LPA in Tyrode's buffer containing  0.2% fatty acid-free bovine albumin 
at 37°C for 45 min. The coverslips were washed, fixed, permeabilized and incubated with rhodamine-conjugated  phalloidin to stain actin 
microfilament bundles (B, D, F, and H), mounted, and photographed.  Fibronectin  bound in linear arrays at cell edges or where cells over- 
lapped. Organized actin was detected at these locations as well. However, most organized actin was not associated with bound fibronectin, 
and fibronectin did localize to areas where there was no organized  actin (arrowheads).  Bar,  10/.tin. 
Zhang et al. Fibronectin and Lysophosphatidic Acid  1455 blasts,  FITC-fibronectin was  found in linear arrays on the 
edges of cells and where cells overlapped (Fig.  10, Cand G). 
More labeled protein was present on the LPA-treated  cells 
than on control cells (compare Fig.  10, A, C, and E to G). 
This pattern represented specific binding inasmuch as little 
fluorescence was detected when unlabeled fibronectin, 500 
txg/ml,  was  included  during  the  incubation  with  FITC- 
labeled fibronectin (not shown). Furthermore, FITC-labeled 
70-kD fragment bound in a similar distribution (not shown). 
Along the central bodies of cells, bound fibronectin was in- 
variably associated with underlying organized actin. Actin 
bundles were also found in areas of cell overlap, but the dis- 
tribution of actin did not correspond exactly with the arrays 
of bound fibronectin (compare Fig. 10, C and D). Some ar- 
rays of bound fibronectin extended for long distances and 
were not associated at all with stainable actin bundles (com- 
pare Fig.  10,  G and H). By low voltage scanning electron 
microscopy, FITC-labeled fibronectin was found in regions 
where filopodia were numerous (Fig.  9,  C and D).  Anti- 
body-coated beads were arranged in lines on nearby dorsal 
surfaces and edges of cells or on the filopodia themselves. 
Discussion 
LPA Is the Major Enhancer of  Fibronectin Assembly in 
Whole Blood Serum 
We have  shown previously that serum,  lipoproteins,  and 
purified LPA enhance the binding fibronectin to MG63 os- 
teosarcoma cells and normal fibroblasts (Checovich et al., 
1992;  Checovich and Mosher,  1993).  Whole blood serum 
has been estimated to contain 1-5/xM LPA whereas no LPA 
was detected in plasma prepared by methods that minimize 
platelet  activation  (Eichholtz  et  al.,  1993).  The  present 
results indicate that LPA is the serum enhancement factor by 
showing that whole blood serum but not plasma or platelet- 
poor serum enhances the binding of fibronectin. Further- 
more, the enhancement activity of whole blood serum is de- 
stroyed by treatment with phospholipase B that renders LPA 
inactive. In our published lipoprotein studies (Checovich et 
al., 1992), lipoprotein fractions had higher specific enhance- 
ment activity than human serum, but substantial enhance- 
ment activity was present in serum depleted of lipoproteins. 
In other studies, the enhancement activity was gradually lost 
during fractionation of serum on anion-exchange and gel 
filtration columns; before being lost, the activity was present 
in albumin-containing fractions (Deetz,  D.  C.,  and D.  E 
Mosher,  unpublished  data).  Similarly,  Ridley  and  Hall 
(1992) found that serum stress fiber-inducing activity frac- 
tionated with albumin on a gel filtration column. Radiola- 
beled LPA binds to purified albumin (Eichholtz et al., 1993). 
LPA derivatized with a photoreactive group can be cross- 
linked in serum to a 68-kD protein, presumably albumin, 
and to 28- and 15-kD proteins (van der Bend et al., 1992). 
We feel, therefore, that all of our purification data can be ex- 
plained in retrospect by LPA. 
LPA Likely Synergizes with Other Products of  Blood 
Coagulation to Modulate Wound Healing 
The effects  of serum on fibronectin binding are probably 
more complicated than the effect only of LPA. Serum mole- 
cules that might synergize with LPA include transforming 
growth factor-~ and platelet-derived growth factor, both of 
which have been shown to enhance the assembly of fibronec- 
tin (Allen-Hoffmann et al., 1988, 1990). In addition, cross- 
talk between LPA and platelet-derived growth factor on tyro- 
sine  phosphorylation of focal  adhesion  kinase  has  been 
demonstrated recently (Seufferleain and Rosengurt, 1994). 
As with LPA, serum concentrations of transforming growth 
factor-/3 and platelet-derived growth factor depend upon ac- 
tivation of platelets (see Mosher et al., 1985, among others). 
LPA-induced up-regulation of matrix assembly may be an 
important part of the wound healing process. Healing of gap- 
ing  wounds  occurs  in  several  stages-population  of the 
wound space by fibroblasts,  elaboration of a  fibronectin- 
collagen matrix, and alignment of fibroblasts within the ma- 
trix, and contraction of the wound (Welch et al., 1990; Grin- 
nell, 1994). LPA and the other products of activated platelets 
potentially could function in each of the stages. 
The Target of  LPA Is Cells but Not Fibronectin 
The observation that lipoproteins had to be present simul- 
taneously with radiolabeled fibronectin in order to detect en- 
hanced binding led us to speculate that enhancement is due 
to a direct interaction between fibronectin and lipoproteins 
(Checovich et al., 1992).  Serum also has to present simul- 
taneously to cause enhanced binding (Assadi, E  M., and 
D. E Mosher, unpublished data). All experiments with LPA, 
however, indicate that the phospholipid works by its effects 
on cells and that the primary effect is to enhance expression 
of the cell-binding sites for modules in the amino-terminal 
portion of fibronectin. Binding of fibronectin over a 330-fold 
concentration range or of the 70-kD amino-terminal frag- 
ment was enhanced by the nanomolar concentrations of LPA 
known to cause perturbations of intracellular signaling path- 
ways and changes in cell shape and cytoskeletal arrangement 
(see Introduction). There was good agreement between the 
effects LPA had on cell shape or actin microfilaments and its 
effect on fibronectin binding in several different experiments. 
In particular, changes in cell shape induced by addition or 
withdrawal of LPA were rapid enough to account for the re- 
quirement that the enhancer be present during the binding 
assay. 
Several known effectors of fibronectin binding act on path- 
ways known to be influenced by LPA. The inhibition of ade- 
nylate cyclase upon treatment with LPA (van Corven et al., 
1989) is in accord with the observation that agents which in- 
crease intracellular cAMP levels cause reduced numbers of 
binding sites for fibronectin or the 70-kD amino-terminal 
fragment (Allen-Hoffmann and Mosher, 1987). Stimulation 
of phospholipase C  and phosphoinositide hydrolysis upon 
treatment with LPA (van Corven et al.,  1989) is in accord 
with the observation that activation of protein kinase C by 
phorbol esters  causes increased numbers of binding sites 
(Somers and Mosher,  1993).  Treatment of cells with cyto- 
chalasin  D  causes  both  loss  of fibronectin binding  sites 
(Barry and Mosher, 1988) and inhibition of LPA-stimulated 
tyrosine phosphorylation (Seufferlein and Rozengurt, 1994). 
The Effect of  LPA on l~bronectin Binding Is Specific 
and Unique 
The concentrations of purified LPA that enhance fibronectin 
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than the critical micellar concentration of LPA, estimated to 
be 70 #M by Das and Hajra (1992) and 1.3 mM by Jalink 
et al. (1990). Other lysophospholipids are inactive, and phos- 
phatidic acid is >100-fold less active than LPA (Checovich 
and Mosher, 1993), demonstrating the specificity of the LPA 
response. Evidence for the existence of a specific cell sur- 
face receptor for LPA is presented in the Introduction. Such 
a receptor, however, has not yet been characterized and re- 
mains hypothetical. Bradykinin, a  peptide  agonist of the 
thrombin receptor,  platelet-activating factor, and LPA all 
elevate cytosolic calcium level in suspended fibroblasts (Ja- 
link et al.,  1990;  Ye et al.,  1991; Jalink and Moolenaar, 
1992).  The calcium response to  LPA,  as  with the  other 
agents, is transient and subject to desensitization (Jalink et 
al., 1990). The enhancement of fibronectin binding to osteo- 
sarcoma cells by LPA, however, was sustained and only lost 
when LPA was removed or the medium became depleted of 
LPA. Bombesin, which most clearly duplicates the effects of 
LPA on cytoskeleton (Ridiey and Hall,  1992),  did not en- 
hance binding of the 70-kD fragment by osteosarcoma cells. 
A peptide agonist of the thrombin receptor, which mimics 
the effects of LPA on neuronal cell retractions (Jalink et al., 
1994), also did not enhance binding. Our observations indi- 
cate, therefore, that LP/fs effects are specific and represent 
a response that is unique among agents that elevate intracel- 
lular calcium ion or trigger cytoskeletal organization. 
The "Fibronectin  Assembly Receptor" Must be Subject 
to Rapid Up- and Down-regulation 
Studies of deletion and mutation sets of the recombinant 
fragment indicate that the amino-terminal five type I mod- 
ules act as a unit that mediates binding to cells (Sottile et al., 
1991). Proteins of 60-70 kD have been isolated from deter- 
gent extracts of macrophages (Blystone and Kaplan,  1992) 
and myoblasts (Moon et al., 1994) that bind to a subfragment 
of the 70-kD fragment that contains the five type I modules. 
Assembly of fibronectin requires fibronectin-fibronectin in- 
teractions, raising the possibility that the binding molecule 
on cell surfaces is fibronectin itself. A fibronectin-fibronec- 
tin interaction site had been identified in the most amino- 
terminal type III module of fibronectin (Chernousov et al., 
1991; Morla and Ruoslahti, 1992).  Morla et al. (1994) sug- 
gested that assembly of fibronectin is controlled by exposure 
of cryptic binding activity in the III-1 module. Hocking et al. 
(1994) demonstrated binding of the 70-kD amino-terminal 
fragment to the III-1 module. However, studies of a dimeric 
construct of the 70-kD region that has the ability to assemble 
into extraceUular matrix suggest that the determinants for 
binding to cell surfaces and interaction with other regions of 
fibronectin  are  different  (Sottile  and  Wiley,  1994).  Our 
results indicate that if the III-1 module of fibronectin or the 
60-70-kD cell surface proteins mediate binding of the 70-kD 
fragment to cell surfaces, a mechanism to cause rapid con- 
formational change must exist to  up-  and down-regulate 
binding activity. 
Binding Data Require both the Interconversion of 
Binding Sites between High and Low Avidity States and 
the Appearance and Disappearance of  Sites 
Increased binding of the 70-kD amino-terminal fragment to 
LPA-treated osteosarcoma cells was due to a  doubling of 
number of binding sites and a threefold increase of avidity 
of binding. Analyses of equilibrium binding over 1,000-fold 
concentration range of input ligand were compatible with 
single, uncooperative classes of binding sites on both LPA- 
treated and control cells.  We found no evidence for low 
avidity sites on LPA-treated cells or a  population of high 
avidity sites on control cells, even though our experiments 
would have allowed detection of such sites. When ligand was 
bound in the presence or absence of LPA and dissociation 
was measured in medium containing or not containing LPA, 
the dissociation rates were independent of the conditions of 
binding but  dependent on the  conditions of dissociation. 
Thus, some binding sites on LPA-treated and control cells 
seem to interconvert between high and low avidity states 
whereas other high avidity sites appear and disappear com- 
pletely. The localization of bound FITC-labeled fibronectin 
shown in Fig. 9 agrees with previous results that localized 
bound fibronectin-gold bead conjugates to lateral and re- 
tracting cell edges and filopodia (Peters and Mosher, 1987a, 
b). We speculate that the binding kinetics can be explained 
by the microscopic fndings. The interconversion between 
high and low avidity binding sites upon addition and with- 
drawal of LPA may be related to polymerization and depoly- 
merization of the actin cytoskeleton whereas the appearance 
and disappearance of high avidity binding sites may be due 
to the protrusion and retraction of filopodial processes. 
The Role of  as/31 Integrin in Fibronectin  Assembly May 
Be to Facilitate Changes in Cell Shape 
The c~5~t fibronectin cell adhesion receptor  is  subject to 
such an up- and down-regulation of its ability to bind fibro- 
nectin (OToole et al.,  1994)  and therefore is an attractive 
candidate for a cell surface binding molecule. In CHO cells, 
expression of ot5/3~ greatly favors elaboration of fibronectin 
matrix (Giancotti and Ruoslahti,  1990;  Wu et al.,  1993). 
Monoclonal  antibodies  to  ol5/3~ block  fibronectin  matrix 
formation (Akiyama et al., 1989) and binding of exogenous 
fibronectin or the 70-kD fragment to cell monolayers (Fo- 
gerty et al., 1990). Cultured mouse cells and mouse embryos 
lacking ors, however, deposit a normal fibronectin matrix as 
assessed  by  immunofluorescence  (Yang  et  al.,  1993). 
Detergent-solubilized cq/3~ does not bind to the 70-kD frag- 
ment (Fogerty et al., 1990).  There is a 10-15-min delay be- 
fore antibody to o~s/31 causes a decrease in fibronectin bind- 
ing to adherent cells (Fogerty et al.,  1990).  We have seen 
similar effects of anti-/3~ on LPA-treated cells;  when LPA 
and antibody were added together, an inhibitory effect of the 
antibody  was  only  evident after  15-20  min  (Zhang  and 
Mosher,  unpublished  observation).  Anti-~  also  causes 
changes in cell shape and alterations in the association of 
cells with preexisting matrix (Fogerty and Mosher,  1990), 
whereas LPA causes a rapid increase in the number of focal 
contacts (Ridley and Hall, 1992). Our studies were done on 
confluent cultures in which the binding sites are on the dorsal 
(upper and lateral) surfaces of cells rich in filopodia. We 
have considered two hypotheses by which the effects of LPA 
on focal contacts and the effects of cts/3~-perturbing agents 
could be related to our results.  First, the same molecules 
Zhang et al. Fibronectin  and Lysophosphatidic Acid  1457 responsible for focal adhesions could be used in a more dy- 
namic fashion to bind the 70-kD fragment.  In favor of this 
scenario is the observation that the 70-kD  fragment local- 
izes to/3~-containing  focal adhesions of newly spread cells 
(Dzamba  et  al.,  1994).  Second,  increased  focal  contacts 
could allow cells to "grip" the substratum and facilitate shape 
change, development of filopodia, and display of molecules 
unrelated to ol5/31 that bind the amino-terminal modules of 
fibronectin. The ability of LPA to regulate cell shape and dis- 
play of assembly sites rapidly and coordinately provides an 
experimental  system in which to test these hypotheses and 
identify the molecules at the assembly  sites. 
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